Anna N Kolomeets1, Vici Varghese, Philippe Lemey, Marina R Bobkova, Robert W Shafer. 1. aOmsk Research Institute of Natural Focal Infections; Siberian Federal District Center For AIDS Prevention and Fight; Omsk, Russia bDivision of Infectious Diseases, Stanford University, Stanford, California, USA cDepartment of Microbiology and Immunology, REGA Institute KU Leuven, University of Leuven, Leuven, Belgium dIvanovsky Research Institute of Virology, Russian Ministry of Health, Moscow, Russia.
Abstract
BACKGROUND: The subtype A variant in the Former Soviet Union (A(FSU)) causes most of Russia's HIV-1 infections. However, the spectrum of drug-resistance mutations (DRMs) in antiretroviral experienced patients with this variant has not been studied. METHODS: Between 2010 and 2013, genotypic resistance testing was performed on plasma samples from 366 antiretroviral-experienced patients in Siberia. RESULTS: Three-hundred patients (82%) had subtype A(FSU) and 55 (15%) had CRF02_AG viruses. The pattern of DRMs was consistent with patient antiretroviral history with one exception. G190S was the most common nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutation, occurring in 55 (33%) subtype A(FSU) viruses from 167 NNRTI-experienced patients compared with none of 37 CRF02_AG viruses from NNRTI-experienced patients (P < 0.001). The next most common subtype A(FSU) NNRTI-resistance mutation, K103N, occurred in 25 (15%) viruses. Wild-type glycine (G) at position 190 is encoded by GGC in more than 99% of published A(FSU) strains. By contrast, G190 is encoded by GGA or GGG in 97% of other subtypes and in subtype A strains outside of the FSU. Therefore, G190S results from a single G→A transition: G (GGC) → S (AGC) almost exclusively in subtype A(FSU) viruses. CONCLUSION: The predisposition of subtype A(FSU) to G190S is concerning because G→A is the most common HIV-1 mutation and because G190S causes higher levels of nevirapine and efavirenz resistance than K103N. This study exemplifies the need for characterizing the genetic mechanisms of resistance in diverse populations and warrants studies to verify that NRTI/NNRTI regimens are as efficacious in treating subtype A(FSU) as viruses belonging to other subtypes.
BACKGROUND: The subtype A variant in the Former Soviet Union (A(FSU)) causes most of Russia's HIV-1 infections. However, the spectrum of drug-resistance mutations (DRMs) in antiretroviral experienced patients with this variant has not been studied. METHODS: Between 2010 and 2013, genotypic resistance testing was performed on plasma samples from 366 antiretroviral-experienced patients in Siberia. RESULTS: Three-hundred patients (82%) had subtype A(FSU) and 55 (15%) had CRF02_AG viruses. The pattern of DRMs was consistent with patient antiretroviral history with one exception. G190S was the most common nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutation, occurring in 55 (33%) subtype A(FSU) viruses from 167 NNRTI-experienced patients compared with none of 37 CRF02_AG viruses from NNRTI-experienced patients (P < 0.001). The next most common subtype A(FSU) NNRTI-resistance mutation, K103N, occurred in 25 (15%) viruses. Wild-type glycine (G) at position 190 is encoded by GGC in more than 99% of published A(FSU) strains. By contrast, G190 is encoded by GGA or GGG in 97% of other subtypes and in subtype A strains outside of the FSU. Therefore, G190S results from a single G→A transition: G (GGC) → S (AGC) almost exclusively in subtype A(FSU) viruses. CONCLUSION: The predisposition of subtype A(FSU) to G190S is concerning because G→A is the most common HIV-1 mutation and because G190S causes higher levels of nevirapine and efavirenz resistance than K103N. This study exemplifies the need for characterizing the genetic mechanisms of resistance in diverse populations and warrants studies to verify that NRTI/NNRTI regimens are as efficacious in treating subtype A(FSU) as viruses belonging to other subtypes.
Authors: Maarja Adojaan; Toomas Kivisild; Andres Männik; Tõnu Krispin; Valentina Ustina; Kai Zilmer; Elo Liebert; Nikolai Jaroslavtsev; Ludmilla Priimägi; Valentina Tefanova; Jelena Schmidt; Kai Krohn; Richard Villems; Mika Salminen; Mart Ustav Journal: J Acquir Immune Defic Syndr Date: 2005-08-15 Impact factor: 3.731
Authors: Olga A Rumyantseva; Igor A Olkhovskiy; Marina A Malysheva; Ludmila A Ruzaeva; Alexander V Vasiliev; Elena V Kazennova; Marina R Bobkova; Vladimir V Lukashov Journal: AIDS Res Hum Retroviruses Date: 2009-09 Impact factor: 2.205
Authors: Johan Vingerhoets; Lotke Tambuyzer; Hilde Azijn; Annemie Hoogstoel; Steven Nijs; Monika Peeters; Marie-Pierre de Béthune; Goedele De Smedt; Brian Woodfall; Gastón Picchio Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Evguenia S Svarovskaia; Joy Y Feng; Nicolas A Margot; Florence Myrick; Derrick Goodman; John K Ly; Kirsten L White; Nilima Kutty; Ruth Wang; Katyna Borroto-Esoda; Michael D Miller Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731
Authors: Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman Journal: Clin Infect Dis Date: 2015-02-13 Impact factor: 9.079
Authors: Natalya M Gashnikova; Ekaterina M Astakhova; Mariya P Gashnikova; Evgeniy F Bocharov; Svetlana V Petrova; Olga A Pun'ko; Alexander V Popkov; Aleksey V Totmenin Journal: Biomed Res Int Date: 2016-11-13 Impact factor: 3.411
Authors: Elizabeth M Etta; Lufuno Mavhandu; Cecile Manhaeve; Keanan McGonigle; Patrick Jackson; David Rekosh; Marie-Louise Hammarskjold; Pascal O Bessong; Denis M Tebit Journal: AIDS Res Ther Date: 2017-07-27 Impact factor: 2.250
Authors: Marcel Tongo; Gordon W Harkins; Jeffrey R Dorfman; Erik Billings; Sodsai Tovanabutra; Tulio de Oliveira; Darren P Martin Journal: Virus Evol Date: 2018-02-19
Authors: Madita Schlösser; Vladimir V Kartashev; Visa H Mikkola; Andrey Shemshura; Sergey Saukhat; Dmitriy Kolpakov; Alexandr Suladze; Tatiana Tverdokhlebova; Katharina Hutt; Eva Heger; Elena Knops; Michael Böhm; Veronica Di Cristanziano; Rolf Kaiser; Anders Sönnerborg; Maurizio Zazzi; Marina Bobkova; Saleta Sierra Journal: Viruses Date: 2020-04-22 Impact factor: 5.048